XOMA

+ Watchlist + Portfolio

XOMA Royalty Corp.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Fundamentals are temporarily unavailable for XOMA.

XOMA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$6.03M	$4.76M	$10.22M	$11.66M
Research & Development	$153.00K	$143.00K	$2.88M	$1.71M
Selling, General & Admin	$23.19M	$25.61M	$34.48M	$36.09M
Operating Expenses	$23.44M	$28.22M	$50.20M	$276.00K
Operating Income	-$17.41M	-$23.46M	-$39.98M	$11.38M
EBITDA	-$17.02M	-$39.36M	-$5.42M	$47.82M
Pretax Income	-$17.12M	-$40.83M	-$19.48M	$31.82M
Income Tax	-$15.00K	$0.00	-$5.66M	$103.00K
Net Income	-$17.10M	-$40.83M	-$13.82M	$31.71M

XOMA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$57.83M	$153.29M	$101.65M	$82.91M
Receivables	$2.37M	$15.22M	$17.02M	$27.68M
Current Assets	$61.25M	$169.31M	$125.60M	$117.26M
Total Assets	$140.38M	$234.30M	$221.28M	$272.70M
Current Liabilities	$6.82M	$19.50M	$24.37M	$34.82M
Long-Term Debt	—	$118.52M	$106.88M	$96.45M
Total Debt	$34.00K	$124.45M	$119.20M	$131.56M
Total Liabilities	$16.37M	$145.58M	$159.38M	$188.76M
Retained Earnings	-$1.18B	-$1.22B	-$1.24B	-$1.22B
Shareholders' Equity	$124.01M	$88.72M	$61.90M	$83.94M
Working Capital	$54.44M	$149.81M	$101.23M	$82.44M
Net Debt	—	—	$16.61M	$26.07M

XOMA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.88M	-$18.16M	-$13.75M	$2.87M
Capital Expenditure	-$15.25M	-$17.00K	-$20.00K	-$20.73M
Free Cash Flow	-$28.13M	-$18.18M	-$13.77M	-$17.85M
Depreciation & Amortisation	$104.00K	$900.00K	$216.00K	$2.97M
Stock-Based Compensation	$3.61M	$9.10M	$10.31M	$9.27M
Investing Cash Flow	-$20.22M	-$711.00K	-$28.26M	$50.89M
Financing Cash Flow	-$4.45M	$120.59M	-$11.13M	-$26.46M
Dividends Paid	-$5.47M	-$5.47M	-$5.47M	-$5.47M
Share Repurchases	—	$0.00	-$13.00K	-$16.71M
Net Change in Cash	-$37.55M	$101.72M	-$53.13M	$27.29M

XOMA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$4.32M	$5.38M	$532.00K	$1.43M	$310.00K
Research & Development	$1.29M	$69.00K	$69.00K	$281.00K	$49.00K
Selling, General & Admin	$8.15M	$7.80M	$9.73M	$10.41M	$11.86M
Operating Expenses	-$1.61M	$776.00K	$1.86M	-$750.00K	$790.00K
Operating Income	$5.93M	$4.60M	-$1.33M	$2.18M	-$480.00K
EBITDA	$6.38M	$13.09M	$18.28M	$10.07M	$8.72M
Pretax Income	$2.37M	$9.19M	$14.10M	$6.16M	$4.47M
Income Tax	$0.00	—	$49.00K	$54.00K	$1.00K
Net Income	$2.37M	$9.19M	$14.05M	$6.10M	$4.46M

XOMA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$90.27M	$75.06M	$45.19M	$82.91M	$85.60M
Receivables	$18.20M	$20.48M	$17.74M	$27.68M	$23.32M
Current Assets	$113.22M	$104.92M	$110.71M	$117.26M	$118.75M
Total Assets	$212.75M	$223.46M	$263.15M	$272.70M	$271.86M
Current Liabilities	$20.43M	$21.50M	$28.30M	$34.82M	$33.08M
Long-Term Debt	$99.93M	$102.20M	$94.38M	$96.45M	$88.83M
Total Debt	$114.45M	$114.58M	$131.91M	$131.56M	$124.73M
Total Liabilities	$128.12M	$131.00M	$155.19M	$188.76M	$158.96M
Retained Earnings	-$1.24B	-$1.23B	-$1.21B	-$1.22B	-$1.22B
Shareholders' Equity	$84.63M	$92.45M	$107.96M	$83.94M	$112.89M
Working Capital	$92.79M	$83.43M	$82.40M	$82.44M	$85.67M
Net Debt	$23.37M	$38.81M	$63.54M	$26.07M	$17.24M

XOMA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$2.20M	$6.47M	-$296.00K	-$5.50M	$6.12M
Capital Expenditure	—	—	-$111.00K	—	—
Free Cash Flow	$2.20M	-$14.14M	-$407.00K	-$5.50M	$6.12M
Depreciation & Amortisation	$547.00K	$658.00K	$880.00K	$887.00K	$895.00K
Stock-Based Compensation	$1.98M	$1.60M	$1.77M	$3.92M	$2.28M
Investing Cash Flow	-$6.69M	-$19.98M	$58.21M	$19.35M	$6.55M
Financing Cash Flow	-$6.89M	-$3.03M	-$5.85M	-$10.69M	-$7.64M
Dividends Paid	-$1.37M	-$1.37M	-$1.37M	-$1.37M	-$1.42M
Share Repurchases	-$545.00K	-$1.82M	-$25.00K	-$14.32M	-$264.00K
Net Change in Cash	-$11.39M	-$16.54M	$52.07M	$3.16M	$5.03M

Market Snapshot

About

XOMA Royalty Corporation is a biotechnology royalty aggregator that acquires the right to milestone and royalty payments associated with commercialized and clinical-stage drug products. The company provides non-dilutive funding to biotechnology companies in exchange for economic rights to future product revenues. XOMA manages a diversified portfolio of assets across multiple therapeutic areas and development stages.